eLabNotebook
> Nucleic Acid Prep
& Purification > Genomic
DNA Purification > Promega MagneSil*
ONE
Biomek® FX
Promega's MagneSil* ONE, Fixed Yield Blood Genomic System on the Biomek® FX
Promega Corporation – www.promega.com
Access to the human genome and other complete genome sequences is playing
an increasingly important role in many research fields.To this end, many
novel genotyping methods have been developed in addition to single-locus
amplification. These systems often rely on analysis of small amounts of
DNA but may be limited to a defined range of input DNA for maximum reproducibility.
Currently, the downstream application requirement for a narrow range of
input DNA adds time and labor to DNA quantitation and normalization.
The MagneSil* ONE, Fixed Yield Blood Genomic System(a) is designed for
the purification of a “fixed yield” of DNA ranging from 500–1500ng
with an average yield of 1µg from 60µl of anti-coagulated
whole blood, thus eliminating the need to quantitate the yield and normalize
post-purification. Specific instructions are provided for the Beckman
Coulter Biomek FX automated liquid handling workstation. A validated method
for this automated liquid handling workstation can be requested at:
www.promega.com/automethods/
General automation guidelines are provided for adaptation to other liquid
handling platforms. The Biomek FX can process 96 samples in approximately
1 hour and requires no hands-on time once the samples are placed on the
robot.
The DNA purified from these samples can be used in STR and PCR(b) analysis
as well as more stringent applications such as multiplexed PCR (e.g.,
Promega’s Y Chromosome Deletion Detection System(c), Cat.# MD1101)
or the READIT* Assay(d), Cat.# MD1290.
The MagneSil* ONE System uses MagneSil* Paramagnetic Particles (PMPs)(a)-Fixed
Yield, which can be considered a “mobile solid phase”. Unlike
column-based systems, the binding of nucleic acids to magnetic particles
can occur in solution, resulting in increased binding kinetics and binding
efficiency. Particles can also be completely resuspended during the wash
steps of a purification protocol, thus enhancing the contact with, and
removal of, contaminants, increasing nucleic acid purity.
* All trademarks are the property of their respective owners. Where applicable,
the PCR process is covered by patents owned by Roche Molecular Systems,
Inc., and F. Hoffman-LaRoche, Ltd.
eLabNotebook
Sitemap
©1998 - 2006 Beckman Coulter, Inc.
